GLP-1 and GIP Combination for Weight Loss & Metabolic Health
Promising New Therapy Shows Important Weight Loss and Metabolic Improvements in Phase 2 Trial
Table of Contents
New York, NY – July 16, 2025 – A groundbreaking Phase 2 clinical trial has revealed the significant potential of maridebart cafraglutide, a novel therapeutic agent, in addressing obesity and its associated metabolic complications. The study, which investigated the efficacy and safety of the drug administered once monthly, demonstrated substantial weight reduction and notable improvements in cardiometabolic markers, offering a beacon of hope for individuals struggling with these widespread health challenges.
Substantial Weight Reduction Achieved
The trial results,presented at the American Diabetes Association 85th Scientific Sessions,highlighted an impressive average weight loss of 15.1% in participants treated with maridebart cafraglutide over a 52-week period. This significant reduction far surpassed the 1.4% weight loss observed in the placebo arm. Crucially, the study indicated that weight loss had not reached a plateau by the end of the trial, suggesting that continued treatment could lead to even greater reductions.
“In this Phase 2 study, participants living with obesity treated with maridebart cafraglutide had substantial weight reduction at 52 weeks without reaching a weight plateau,” stated Ania Jastreboff, MD, PhD, a leading expert in obesity research and professor at Yale School of Medicine. “These findings are particularly encouraging as we seek sustainable, long-term treatments for people living with obesity.”
Metabolic Health Benefits Beyond Weight Loss
Beyond its impact on weight, maridebart cafraglutide also demonstrated a positive effect on glycemic control and other key cardiometabolic indicators. In individuals with obesity and type 2 diabetes (T2D), the therapy lead to a reduction in HbA1c levels of up to 2.2%.Furthermore, the study reported significant improvements in pre-specified cardiometabolic markers, including reductions in waist circumference, enhanced blood pressure readings, decreased levels of high-sensitivity C-reactive protein, and favorable adjustments in select lipid profiles.
“These data demonstrate the potential for once-monthly or less frequent dosing and are particularly encouraging as we seek sustainable,long-term treatments for people living with obesity,with and without T2D,” Dr. Jastreboff added.
Safety Profile and Future Outlook
The safety profile of maridebart cafraglutide was also evaluated, with the most commonly reported adverse events being gastrointestinal in nature. these events were generally mild to moderate in severity and were considered tolerable within the context of the GLP-1 class of medications. Importantly, no new safety signals were identified during the trial.
The promising results from this Phase 2 study, coupled with earlier pharmacokinetic data, have directly informed the design of the Phase 3 MARITIME program. “Maridebart cafraglutide’s monthly or less frequent dosing has the potential to improve adherence and long-term weight control, providing the prospect to optimize health outcomes for people living with obesity, T2D, and related conditions,” concluded Bradner, a key figure in the drug’s advancement.
The triumphant outcomes of this trial mark a significant step forward in the development of new therapeutic options for obesity and related metabolic disorders, with the potential to profoundly impact public health.
References
- Jastreboff A.,Ryan D., Bays H., et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity – A Phase 2 Trial. The New England Journal of Medicine. (2025) Two: 10.1056/Nejmoa2504214
- Results From Amgen’s Phase 2 Obesity Study of Monthly MariTide Presented At The American Diabetes Association 85th Scientific Sessions.Amgen. News release. June 23, 2025. Accessed July 16, 2025. https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions